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Performance of a cardiac lipid panel 
compared to four prognostic scores 
in chronic heart failure
Peter McGranaghan1,2,12, Anshul Saxena2,12, Hans‑Dirk Düngen1, Muni Rubens2, 
Sandeep Appunni3, Joseph Salami2, Emir Veledar2,10,11, Philipp Lacour1, Florian Blaschke1, 
Danilo Obradovic4, Goran Loncar5, Elvis Tahirovic6, Frank Edelmann1,7,8, 
Burkert Pieske1,7,8,9 & Tobias Daniel Trippel1,7*
The cardiac lipid panel (CLP) is a novel panel of metabolomic biomarkers that has previously shown 
to improve the diagnostic and prognostic value for CHF patients. Several prognostic scores have been 
developed for cardiovascular disease risk, but their use is limited to specific populations and precision 
is still inadequate. We compared a risk score using the CLP plus NT‑proBNP to four commonly used 
risk scores: The Seattle Heart Failure Model (SHFM), Framingham risk score (FRS), Barcelona bio‑HF 
(BCN Bio‑HF) and Meta‑Analysis Global Group in Chronic Heart Failure (MAGGIC) score. We included 
280 elderly CHF patients from the Cardiac Insufficiency Bisoprolol Study in Elderly trial. Cox Regression 
and hierarchical cluster analysis was performed. Integrated area under the curves (IAUC) was used 
as criterium for comparison. The mean (SD) follow‑up period was 81 (33) months, and 95 (34%) 
subjects met the primary endpoint. The IAUC for FRS was 0.53, SHFM 0.61, BCN Bio‑HF 0.72, MAGGIC 
0.68, and CLP 0.78. Subjects were partitioned into three risk clusters: low, moderate, high with the 
CLP score showing the best ability to group patients into their respective risk cluster. A risk score 
composed of a novel panel of metabolite biomarkers plus NT‑proBNP outperformed other common 
prognostic scores in predicting 10‑year cardiovascular death in elderly ambulatory CHF patients. This 
approach could improve the clinical risk assessment of CHF patients.
The prevalence of chronic heart failure (CHF) in the western world continues to increase, especially in patients 
older than 65  years1. CHF is a major burden on the health care system and is associated with high morbidity 
and mortality, including a poor quality of  life2. An important aspect of CHF management is to ensure that clini-
cians and patients with CHF have the necessary knowledge and resources to make the best health decisions. A 
prognostic model is one such resource, defined as a formal combination of multiple predictors from which risks 
of a specific outcome can be calculated for individual patients.
Prognostic models are abundant in the literature, and the most popular ones include the SHFM (Seattle Heart 
Failure Model), FRS (Framingham Risk Score), MAGGIC (Meta-analysis Global Group in Chronic Heart Fail-
ure), and BCN Bio-HF (Barcelona Bio-Heart Failure Risk Calculator). The SHFM score is the most thoroughly 
validated and contains the most predictor variables of the  four3. The MAGGIC  score4 was developed from a 
dataset of over 39,000 patients across 30 studies and validated on more than 60,000 patients using 2 large CHF 
 cohorts5,6. The FRS score was developed as a sex-specific risk score that can be conveniently used to calculate 
general cardiovascular disease (CVD) risk and risk of individual CVD  events7. The BCN Bio-HF score contains 11 
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clinical variables with the most biomarker variables [NT-proBNP, high-sensitivity cardiac troponin T (hs-cTnT), 
high-sensitivity soluble ST2 (ST2)] and has been externally  validated8,9. These models all use common clinical 
and demographic variables to predict the prognosis of CHF patients and have convenient online calculators. 
Although these scores have been validated, they have not been widely adopted possibly because they are not 
routinely calculated in clinical  practice10–12, have poor reliability at the individual patient  level5, suffer from a 
significant amount of missing data requiring imputation.
Metabolomics is a rapidly growing field in biomarker profiling that could help meet the need for more robust 
prognostic biomarkers. By applying nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS), it is now possible to analyze hundreds of metabolites from human samples such as blood, urine, saliva, 
and tissue, which can elucidate the outcome of complex networks of endogenous and exogenous biochemical 
 reactions13. This approach could provide a more comprehensive signature of biochemical activities that could 
be associated with diet, medication, disease progression, and thus negative outcomes due to these complex 
 mechanisms14,15. Previous studies have shown that metabolomic biomarkers can be used for risk prediction as 
well as diagnosis of  CHF16–28.
One promising metabolomic biomarker panel in CHF patients is the cardiac lipid panel (CLP) which is sup-
plemented by N-terminal pro–B-type natriuretic peptide (NT-proBNP). The CLP is consists of three specific 
metabolomics features: triacylglycerol (TAG) 18:1/18:0/18:0, phosphatidylcholine (PC) 16:0/18:2, and the sum 
of the 3 isobaric sphingomyelin (SM) species SM d18:1/23:1, SM d18:2/23:0, and SM d17:1/24:1. The diagnostic 
value of CLP was first discovered in a study by Mueller and colleagues, where they compared CHF patients to 
healthy controls, and found that CLP was able to improve the diagnostic performance over NT-proBNP  alone29. 
The incremental prognostic value of the CLP was first assessed in a recent study which found it improved the 
discrimination and risk assessment over NT-proBNP and clinical risk  factors30.
The objective of this study was to compare the performance of a risk score composed of the CLP panel plus 
NT-proBNP to the four commonly used traditional risk scores (SHFM, FRS, MAGGIC, BCN Bio-HF) to pre-
dict long-term cardiovascular mortality in ambulatory CHF patients. We hypothesized that the CLP risk score 
would improve our ability to classify risk of cardiovascular death in comparison to the four validated clinical 
risk prediction algorithms.
Results
Table 1 shows the baseline characteristics of the total population (n = 280) as well as the variables included in each 
score. Mean age of this sub-cohort was 72.1 (4.9) years, 26.4% were women, 45% patients had heart failure with 
reduced ejection fraction (HFrEF) (LVEF < 35%), and most patients were in NYHA functional class II (67.5%) 
with the remaining in NYHA class III. Hypertension was present in 80% of participants and 45% were current or 
former smokers; 29% had diabetes and 71% had CAD. During the follow-up period (mean = 81 months, SD = 33; 
median = 96 months), 95 (34%) patients met the primary outcome. There were 30 (11%) patients who met the 
secondary outcome of 3-year all-cause mortality. The sample selection criteria as well as the comparison of this 
sub cohort’s baseline characteristics to the source cohort has previously been  reported30, however, this study 
analyzed 10 year follow up rather than the previously reported 4 year follow up.
All variables were available for each score except for the lymphocytes (%) variable in the SHFM score, which 
was imputed as previously described. The SHFM model had the highest number of variables (n = 17), followed 
by MAGGIC (n = 13), BCN Bio-HF (n = 12), FRS (n = 7), and CLP (n = 4). There were 13 overlapping variables 
which were included in at least 2 scores. The SHFM score included the most medication (n = 6) and laboratory 
(n = 5) variables, BCN Bio-HF is the only model with biomarker data (NT-proBNP) while MAGGIC included 
the most clinical (n = 7) and demographic variables (n = 3).
Table 2 shows the univariate Cox Regression results. The CLP (HR = 2.38, p < 0.001), SHFM (HR = 2.01, 
p = 0.002, MAGGIC (HR = 1.10, p < 0.001), and BCN Bio-HF (HR = 1.09, p = 0.0393) scores were significantly 
associated with the outcome while FRS was not. The hazard ratios for the secondary endpoint of 3-year all-cause 
mortality are shown in Supplemental Table 1. All scores had a higher HR than the primary outcome except for 
CLP and FRS. Figure 1 shows the AUC change over time (IAUC) for the 5 prognostic scores with the comparison 
of Uno’s concordance statistics for hypothesis testing. The IAUC was 0.53, 0.61, 0.68, 0.72, and 0.78 for FRS, 
SHFM, MAGGIC, BCN Bio-HF, and CLP, respectively. Harrell’s c statistics at 10 year follow up show similar 
results (Supplemental Table 2). The four traditional scores were all significantly different (p < 0.05) from the CLP 
score according to the difference in concordance statistic (Supplemental Table 3). The incremental value of the 
CLP to NT-proBNP is shown in Supplemental Figure 1, the NT-proBNP only IAUC was 0.71 while the CLP 
score (which incorporates the CLP biomarkers plus NT-proBNP) was 0.78 (p = 0.004). Discrimination analysis 
of the secondary outcome of 3-year all-cause mortality showed the CLP IAUC lowered to 0.76, and only CLP vs 
FRS remained significantly different (Supplemental Figure 2). The models showed adequate calibration except 
for FRS (calibration curve slope = 0.894) (Supplemental Figure 3).
Competing event analysis showed the SHFM, MAGGIC, and the CLP models remained significantly associ-
ated with cardiovascular death, and all scores showed less association to non-cardiovascular death (Supplemental 
Table 4). The CIF curve, which accounted for non-cardiovascular mortality as a competing event, showed higher 
cumulative incidence of cardiovascular mortality with higher CLP scores (Supplemental Figure 4).
Figure 2 shows the hierarchical cluster dendrogram mapped to illustrate the assignment of patients into their 
respective clusters and the associated color map shows the range of each prognostic score and their distribution 
within each cluster. Hierarchical clustering grouped the patients in separate clusters accounting for the noise 
between smaller clusters. Each observation was treated as a unique cluster, and this method: (1) identified the two 
similar or close clusters, and (2) merged the two most similar clusters. Using this clustering technique, similar 
prognostic score data from participants were grouped together, such that the members in the same group were 
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n = 280 SHFM FRS MAGGIC BCN Bio-HF CLP
Age (years), mean ± SD 72 ± 4.9 ✓ ✓ ✓ ✓
NYHA (II/III), n 188/91 ✓ ✓ ✓
Male, n (%) 206 (74) ✓ ✓ ✓ ✓
Body mass index (kg/m2), mean ± SD 26.8 ± 3.4 ✓
Heart rate (bpm), mean ± SD 73 ± 13.0
Systolic blood pressure (mm Hg), mean ± SD 134 ± 19 ✓ ✓ ✓
Diastolic blood pressure (mm Hg), mean ± SD 81 ± 11
Years since first diagnosis of CHF 5.2 ± 5.6 ✓
Laboratory, mean ± SD
Creatinine (μmol/L) 107 ± 27.9 ✓
Hemoglobin (g/dL) 13.4 ± 1.5 ✓ ✓
Sodium (mEq/L) 141.4 ± 3.3 ✓ ✓
Uric acid (μmol/L) 356 ± 127 ✓
Total Cholesterol (mmol/L) 5.1 ± 1.6
HDL cholesterol (mmol/L) 1.2 ± 0.5 ✓
LDL cholesterol (mmol/L) 3.4 ± 1.3
Triglycerides (mmol/L) 1.7 ± 1.0
Lymphocytes (%)* ✓
NT-proBNP (pg/mL) 793 (331–1765)† ✓ ✓
PC 16:0/18:2 (µg/dl) 36,810 (32,435–40,015)† ✓
TAG 18:1/18:0/18:0 (µg/dl) 121 (76.5–256.4)† ✓
SM d18:1/23:1, SM d18:2/23:0, SM d17:1/24:1 (µg/dl) 1342 (1134–1596)† ✓
Cardiac imaging, mean ± SD
LVEF (%) 36 ± 9.5 ✓ ✓
LVDed (mm) 58.8 ± 9.2
LVDes (mm) 45.5 ± 9.7
LVVed (mL) 152.7 ± 63.9
LVVes (mL) 101.1 ± 51.6
LAes (mm) 45.3 ± 7.2
E/e’ 12 ± 9.2
E/A 1 ± 0.8
Deceleration time (ms) 226 ± 80
Comorbidities, n (%)
Diabetes 82 (29) ✓ ✓
Hypertension 224 (80)
Coronary artery disease 200 (71) ✓
Smokers 125 (45) ✓ ✓
Hyperlipidemia 162 (58)
COPD 9 (3) ✓
Medication, n (%)
ACE inhibitor 247 (88) ✓ ✓
Allopurinol 0 (0) ✓
ARB 115 (41) ✓ ✓
Beta blocker 203 (73) ✓ ✓
Diuretics 219 (78) ✓




Antiarrhythmic agent 42 (15)
Statin 114 (41) ✓ ✓
Table 1.  Baseline characteristics of the study participants and variables included in each prognostic score. ACE, 
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BCN Bio-HF, Barcelona Bio-Heart Failure 
Risk Calculator; CLP, Cardiac Lipid Panel Risk Score; COPD, chronic obstructive pulmonary disease; E/A, ratio 
of the early (E) to late (A) ventricular filling velocities; E/e’, ratio between early mitral inflow velocity and mitral 
annular early diastolic velocity; FRS, Framingham Risk Score; LAes, left atrial end systole; LDL, low-density 
lipoprotein; NYHA, New York Heart Association; HDL, high-density lipoprotein; LVDed, left ventricular 
diameter end diastole; LVDes, left ventricular diameter end systole; LVVed, left ventricular volume end diastole; 
LVEF, left ventricular ejection fraction; LVVes, left ventricular volume end systole; mg/kg, milligrams per 
kilograms; MAGGIC, Meta-analysis Global Group in Chronic Heart Failure; NTpro-BNP, N-terminal pro–B-
type natriuretic; PC, phosphatidylcholine; SHFM, Seattle Heart Failure Model; SM, sphingomyelin; TAG, 
triacylglycerol. *Imputed using the median, 31%, of the normal range 20–40%. † Median (Interquartile Range).
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more similar to each other than the members in the other groups. We can infer from the cluster centres and 
cluster memberships that CLP risk score was better at grouping patients with respect to their cardiovascular 
mortality risk and associated clinical characteristics compared to the other four scores. The survival curves for 
each risk cluster are shown in Fig. 3. Rates of mortality were: low risk cluster (20%), moderate risk cluster (27%) 
and high-risk cluster (50%). Supplemental Figure 5 shows the constellation plot on a two-dimensional plane 
with nodes and links to describe relationship among component nodes. This plot is an alternate depiction of the 
dendrogram and illustrates the length between clusters and a balanced structure. Supplemental Figure 6 shows 
the scatterplot matrix of all 4 scores and clusters to illustrate the relationships between each prognostic score 
and risk cluster assignment.
Table 3 shows the cohort characteristics and the prognostic score distribution for each risk cluster. The three 
clusters were: low risk, n = 119; moderate risk, n = 44; high risk, n = 117. There were 11 out of the 50 cohort char-
acteristics significantly different across the 3 clusters. In particular, patients in the highest risk cluster were older, 
with lower LVEF, higher NT-proBNP, and experienced a higher frequency of events. The SHFM, BCN Bio-HF, 
and CLP scoreswere significantly different across their respective risk clusters. Of the continuous risk scores 
(FRS, SHFM, MAGGIC, BCN Bio-HF), only SHFM and MAGGIC, had its highest mean score in the high-risk 
cluster. The categorical CLP score showed a skewed distribution of higher risk scores (3–4) in the moderate and 
high-risk clusters. In the high-risk cluster, the majority of subjects were scored with CLP scores of 3–4.
The correlation of the CLP biomarkers TAG, PC, and SM were most correlated with the clinical character-
istics: triglycerides (r = 0.531, p < 0.001), total cholesterol (r = 0.431, p < 0.001), and LDL (r = 0.502, p < 0.001), 
respectively (Supplemental Figure 7).
Discussion
We found that a risk score based on a novel panel of three metabolite-based biomarkers plus NT-proBNP 
outperformed commonly used traditional prognostic models for predicting cardiovascular mortality in elderly 
ambulatory CHF patients. We first measured the association of each risk score with the outcome, followed by 
discrimination analysis, then cluster analysis, and finally correlation analysis of the individual CLP biomarkers 
with the clinical characteristics. In our study cohort, CLP score, showed the best discrimination compared to 
the other 4 scores. This indicates that the biomarker information included in the CLP score could more precisely 
classify high risk CHF patients than the information included in the 4 other risk scores. On the other hand, 
the biomarker information from the CLP is not as easily attainable and no convenient calculator exists yet, as 
these findings should first be validated in larger cohorts. Additionally, none of the other scores were originally 
developed for 10-year cardiovascular mortality. To the best of our knowledge there is no score specific for pre-
dicting 10-year risk of cardiovascular death, but it is not uncommon to use the scores such as FRS to predict 
different outcomes in similar  studies31–33. Nevertheless, the other risk scores may be improved with the addition 
of common biomarkers in their score calculation. For instance, NT-proBNP is a well-established biomarker 
that is known to be associated with ventricular wall  stress34 and is considered the gold-standard biomarker in 
CHF diagnosis and  prognosis35. Only BCN Bio-HF contained NT-proBNP and it was the next best performing 
prognostic score after the CLP.
We performed cluster analysis to assess how well the risk scores could partition subjects into different risk 
groups, blinded to the study outcome. A strength of this approach is that clusters could define relevant groups 
of patients and could mitigate the problems of multicollinearity while determining if the predictive variables are 
useful in separating these groups. In our study, patients within each cluster varied along measures of age, labora-
tory parameters, days survived, as well as the prognostic scores. When comparing the score distributions across 
the three risk clusters, the CLP score showed a more homogenous grouping of patients according to their risk 
score stratification while the other scores showed a more heterogenous distribution across risk clusters. Several 
prior studies have used similar clustering methods to identify clinically relevant patient subgroups for  CHF36,37, 
but we are not aware of previous studies using clustering methods to compare a novel biomarker score to other 
conventional prognostic scores for CHF.
The combination of the CLP’s metabolomic features with NT-proBNP into a risk score may help overcome 
limitations of using only traditional clinical risk factors. Furthermore, application of a single biomarker such 
as NT-proBNP for outcome prediction is limited by insufficient specificity (low predictive value or high false 
positive rate)38,39. Recently, it was reported that the CLP added incremental prognostic value to NT-proBNP in 
Table 2.  Prognostic scores and univariate hazard ratios for cardiovascular mortality. Unadjusted Cox 
proportional hazard models of 10-year outcome for cardiovascular mortality. Total subjects, n = 280. Total 
events, n = 95. SHFM (Seattle Heart Failure Model), FRS (Framingham Risk Score), and MAGGIC (Meta-
analysis Global Group in Chronic Heart Failure), BCN Bio-HF (Barcelona Bio-Heart Failure Risk Calculator), 
and Cardiac Lipid Panel Risk Score (CLP).
Score HR (95% CI) p value
SHFM 1.89 (1.29–2.807) 0.0017
FRS 1.02 (0.97–1.07) 0.5291
MAGGIC 1.10 (1.05–1.14) < .0001
BCN Bio-HF 1.09 (1.00–1.84) 0.0393
CLP 2.38 (1.95–2.92) < .0001
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predicting 4-year cardiovascular  mortality30. We used the same method to calculate the CLP score for this study, 
and we also confirmed that the CLP provided similar incremental value to NT-proBNP alone as previously found 
in the 4-year  study30.Using an aggregate score rather than individual biomarkers for risk prediction can help more 
precisely stratify risk. A recent meta-analysis of 18 metabolomic prognostic biomarker studies for CVD found 
those which incorporated a selection of metabolites into a score (n = 5 studies) had the best prognostic perfor-
mance rather than using the individual biomarker  values16. Another systematic  review20 reported 6  studies21–26 
developed a metabolite-based score to predict CVD risk with each score composed between 4 and 16 biomarkers.
We have briefly mentioned the components of the CLP in the introduction section, in addition to improving 
risk prediction, developing a biomarker-based risk score could also improve our understanding of the patho-
physiology and biological mechanisms involved in CHF. In the following paragraphs we would like to highlight 
those mechanisms based on previous research. The CLP metabolites can be grouped into three different lipid 
subclasses, sphingomyelin (SM) phosphatidylcholine (PC), and triglycerides (TAG), which have previously been 
found to be associated with cardiomyocyte stress/apoptosis40, intestinal microbial metabolism/inflammation19, 
and coronary artery  disease41, respectively. Sphingomyelins are localized in cell membranes and lipoproteins, 
and their hydrolysis by sphingomyelinase leads to increased amounts of ceramide. Ceramide triggers the genera-
tion of reactive oxygen species (ROS) involved in the modulation of cell proliferation and apoptosis, neutrophil 
adhesion to the vessel wall, and vascular tone. Dysfunctional sphingomyelin and ceramide metabolism may lead 
to or aggravate cardiovascular  diseases42. Lemaitre et al.43 reported that lipid species such as Cer-16 and SM-16 
were associated with increased risk of heart failure. Sigruener et al.44 reported that the detection of sphingomy-
elin species SM 16∶0, 16∶1, 24∶1 and 24∶2 was increasingly associated with mortality in Ludwigshafen Risk and 
Cardiovascular Health (LURIC) study. The CLP biomarker panel consists of the sum of three monosaturated 
fatty acid carrying SM species: SM d18:1/23:1, SM d18:2/23:0, SM d17:1/24:1.
PC is the most abundant lipid in the human body and is subjected to chemical events like lipid peroxidation 
and ROS  formation45. Myocardium suffers heavily from lipid peroxidation related  injury46. PC carrying polyun-
saturated fatty acids such as PC (16:0/18:2) which is a component of the CLP panel, have increased risk for lipid 
 peroxidation47. Oxidative stress increases the formation of electrophilic aldehydes from native phospholipids 
leading to formation of adducts with tissue or plasma proteins thereby aggravating the pathophysiology of car-
diovascular  diseases48. Previous studies have shown that lipid peroxidation and ROS generation are associated 
with cardiac damage and raises mortality. Higher consumption of PC was found to increase the risk of organ 
Figure 1.  Discrimination performance for each prognostic score for 10-year cardiovascular mortality. 
Integrated area under the curve (IAUC) for: SHFM (Seattle Heart Failure Model), FRS (Framingham Risk 
Score), and MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), BCN Bio-HF (Barcelona Bio-
Heart Failure Risk Calculator), and Cardiac Lipid Panel Risk Score (CLP). Total subjects, n = 280; total events, 
n = 95. p values were calculated from the differences in concordance statistic in comparison to the CLP score.
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injury and cardiovascular  mortality49. Natural antioxidants like α-tocopherol have shown to reduce such oxida-
tive stress and resulting inflammation thereby preventing the progression of cardiac  injury50.
The molecules of TG are involved in the regulation of insulin-signaling pathways through the activation of 
several serine/threonine kinases, which suppress insulin receptors, thus inducing peripheral insulin resistance. 
Previous studies have shown that insulin resistance leads to inflammation and  atherosclerosis51. Although the 
relationship between total triglycerides and insulin resistance and CVD risk are well  established52, the rela-
tionships between individual serum TGs and insulin resistance is not well-established. Studies of individual 
TGs may help better characterize insulin resistance and CVD better than total triglycerides. For instance, it 
was previously found that saturated TG 16:0 fatty acid was positively associated with fasting serum insulin 
concentrations and that of essential 18:3 n-6 fatty acid was negatively  associated53. Another study on indi-
vidual TGs revealed that serum TG molecules containing saturated and monounsaturated fatty acids, such as 
TG(16:0/16:0/18:1) and TG(16:0/18:1/18:0), correlated positively, whereas those containing essential fatty acids, 
such as TG(18:1/18:2/18:2), negatively with features of insulin  resistance54. The CLP consists of the saturated and 
monosaturated fatty acid carrying TAG 18:1/18:0/18:0.
These findings indicate that metabolomic studies may help gain a deeper understanding of the molecular 
mechanisms of CVD. Therefore, more detailed metabolomic analysis would hopefully lead to the discovery or 
further development of sensitive and specific lipid-based markers for cardiovascular risk.
Figure 2.  Hierarchal cluster dendrogram of three risk clusters. Assignment of patients into risk clusters based 
on the prognostic scores. The clustering process can be viewed by reading the dendrogram from left to right. 
Each step consists of combining the two closest clusters into a single cluster. The joining of clusters is indicated 
by horizontal lines that are connected by vertical lines. The horizontal position of the vertical line represents the 
distance between the two clusters that are most recently joined to form the specified number of clusters. The 
prognostic scores used for clustering were: SHFM (Seattle Heart Failure Model), FRS (Framingham Risk Score), 
and MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), BCN Bio-HF (Barcelona Bio-Heart 
Failure Risk Calculator), and Cardiac Lipid Panel Risk Score (CLP). Each prognostic score was standardized to 
the same scale (mean = 0; SD = 1). Ward’s minimum variance method was used for clustering. Blue dendrogram 
indicates the cluster 1 (low risk), n = 119; Grey dendrogram indicates cluster 2 (moderate risk), n = 44, Red 
dendrogram indicates cluster 3 (high risk), n = 117; Total subjects, n = 280.
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Study limitations
These proof-of-concept findings should be interpreted as hypothesis generating to be used as a reference for 
validation studies on larger cohorts in the future. The homogeneity of this cohort, elderly patients with stable 
CHF, may have had an impact on the performance of the prognostic scores. Due to the inclusion and exclusion 
criteria of the CIBIS-ELD trial, these results may not have good external validity, and more research would be 
needed to validate the results. Performance and comparison of the risk scores may be affected by the fact that 
the models were designed using different endpoint definitions and cohorts. Risk categories that are clinically 
relevant for one model’s definition may not apply to a different model. The MAGGIC score estimates risk of all-
cause mortality at one and at three years, the SHFM up to five years, and the BCN Bio-HF at one, two, and three 
years, and the FRS estimates risk of first CVD event, none of which were developed for the primary outcome 
of this study of 10-year cardiovascular mortality. The SHFM score may have been affected by the imputation of 
lymphocytes % as well as the lack of patients taking allopurinol. The BCN-bio HF score was updated in  201855 
which could provide better predictive value than the 2014 version used in this study. We were limited by the 
availability of the data for the 2018 version of the BCN-bio HF score, since it required more parameters such as 
ARNi medication and number of HF hospitalizations in the previous year. The FRS was originally developed for 
coronary artery disease and not CHF, which may explain its poor performance on this cohort. The CLP biomarker 
kit was developed for routine use in the clinic; however, it is still a research biomarker panel pending regulatory 
approval and must be sent to a lab equipped with MS technology. Our findings are limited to this population of 
elderly CHF patients and future validation studies should be performed to include a more heterogenous cohort 
such as younger, more women, and early/ asymptomatic patients. Other common biomarkers such as ST2, 
hs-CRP, and troponins should be compared to the CLP as they are more readily available and do not require 
samples be sent to a specialized lab. The CLP panel was originally developed as a diagnostic and early detection 
biomarker for HFrEF, and clinicians and researchers should be cautious when using it as a prognostic tool, as 
these are still preliminary findings.
Conclusion
In a cohort of ambulatory CHF patients, we have shown that the prognostic scores included in this study were 
useful in stratifying patients into risk clusters. Our findings demonstrate that the CLP risk score comprising 
a panel of 3 novel metabolomic biomarkers and NT-proBNP, could improve the prediction of cardiovascular 
mortality over traditional prognostic scores. In the future, a broader array of biomarkers should be integrated 
into a more comprehensive risk score that may improve discrimination potential and risk stratification and the 
Figure 3.  Kaplan Meier survival curves for 10-year cardiovascular mortality stratified by each risk cluster. The 
following scores were used to derive the risk clusters: SHFM (Seattle Heart Failure Model), FRS (Framingham 
Risk Score), MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), BCN Bio-HF (Barcelona 
Bio-Heart Failure Risk Calculator), and Cardiac Lipid Panel Risk Score (CLP). Each prognostic score was 
standardized to the same scale (mean = 0; SD = 1). Total subjects, n = 280; total events, n = 95.
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Characteristic
Cluster 1 Cluster 2 Cluster 3
p value
Low risk Moderate risk High risk
n = 119 n = 44 n = 117
Age (years), mean ± SD 71 ± 5.1 71 ± 4.2 73 ± 4.8 0.0058a
NYHA (II/III), n 83/36 35/9 71/46 0.1868c
Male, n (%) 91 (77) 29 (66) 86 (74) 0.3979b
Body mass index (kg/m2), mean ± SD 27.0 ± 3.0 27.0 ± 3.4 26.6 ± 3.9 0.4165a
Heart rate (bpm), mean ± SD 73.8 ± 26.7 72.0 ± 10.9 73.2 ± 12.6 0.9385a
Systolic blood pressure (mm Hg), 
mean ± SD 136 ± 17.7 137 ± 25.7 131 ± 16.9 0.0642
a
Diastolic blood pressure (mm Hg), 
mean ± SD 82.9 ± 10.9 78.7 ± 13.0 79.5 ± 10.3 0.0485
a
Years since first diagnosis of CHF 5.3 ± 5.9 5.0 ± 4.5 5.3 ± 5.7 0.9737a
Cardiac Death, n (%) 24 (20) 12 (27) 59 (50)  < 0.0001b
Laboratory, mean ± SD
Serum creatinine (μmol/l) 103 ± 26.7 104 ± 26.7 113 ± 28.7 0.0034a
Hemoglobin (g/dL) 13.6 ± 1.4 13.4 ± 1.1 13.4 ± 1.7 0.1927a
Sodium (mmol/L) 142 ± 3.2 141 ± 3.6 141 ± 3.2 0.6576a
Uric acid (μmol/L) 342 ± 103 324 ± 108 378 ± 147 0.1084a
Total Cholesterol (mmol/L) 5.1 ± 1.6 5.4 ± 1.4 5.0 ± 1.6 0.2022a
HDL cholesterol (mmol/L) 1.2 ± 0.4 1.2 ± 0.4 1.2 ± 0.5 0.6042a
LDL cholesterol (mmol/L) 3.5 ± 1.4 3.5 ± 1.1 3.3 ± 1.3 0.4337a
Triglycerides (mmol/L) 1.7 ± 0.9 1.7 ± 0.9 1.8 ± 1.0 0.5816a
Lymphocytes (%)* 31 31 31 N/A
NT-proBNP (pg/mL) 506.0 (236–1461)† 860 (369–1883)† 1094 (450–2059)† 0.0015a
PC 16:0/18:2 (µg/dl) 36,830 (33,035–40,460)† 35,300 (30,538–39,370) † 37,275 (31,688–39,850) † 0.3678 a
TAG 18:1/18:0/18:0 (µg/dl) 131 (91–253)† 107 (74–264) † 103 (72–253) † 0.5739 a
SM d18:1/23:1, SM d18:2/23:0, SM 
d17:1/24:1 (µg/dl) 1433 (1181–1613)
† 1378 (1156–1688) † 1296 (1071–1529) † 0.1598a
Cardiac imaging, mean ± SD
LVEF (%) 37.7 ± 9.6 36.7 ± 8.2 34.0 ± 9.5 0.0046a
LVDed (mm) 57.8 ± 9.2 59.6 ± 8.1 59.5 ± 9.5 0.2684a
LVDes (mm) 44.3 ± 9.4 45.6 ± 9.0 46.7 ± 10.1 0.1422a
LVVed (mL) 147 ± 57.5 165 ± 77 154 ± 64.6 0.4697a
LVVes (mL) 95.9 ± 47 109 ± 60.7 104 ± 52.2 0.4449a
LAes (mm) 44.6 ± 6.9 45.3 ± 6.5 45.9 ± 7.7 0.3705a
E/e’ 11.3 ± 8.8 10.4 ± 9.1 13.0 ± 9.5 0.0202a
E/A 1.0 ± 0.6 1.0 ± 0.8 1.2 ± 0.9 0.2407a
Deceleration time (ms) 233 ± 84.8 229 ± 80.8 219 ± 72.8 0.4823a
Comorbidities, n (%)
Diabetes 29 (24) 11 (25) 42 (36) 0.1195b
Hypertension 95 (80) 39 (87) 90 (77) 0.2534b
Coronary artery disease 80 (67) 30 (68) 90 (77) 0.2245b
Smokers 55 (46) 20 (46) 50 (43) 0.8592b
Hyperlipidemia 67(56) 26 (61) 69 (59) 0.8636b
COPD 2 (2) 2 (5) 5 (4) 0.2143b
Medication, n (%)
ACE inhibitor 104 (87) 36 (82) 107 (92) 0.2244b
Allopurinol 0 (0) 0 (0) 0 (0) N/A
ARB 39 (33) 16 (36) 60 (51) 0.0121b
Beta blocker 87 (73) 36 (82) 80 (68) 0.2303b
Diuretics 53 (45) 23 (52) 69 (59) 0.0850b
Diuretic dose mg/kg, mean ± SD 0.28 ± 0.25 0.33 ± 0.35 0.36 ± 0.34 0.3410a
Glycoside 26 (22) 8 (18) 25 (21) 0.8736b
Aspirin 92 (77) 33 (75) 91 (78) 0.9309b
Nitrate 55 (46) 28 (64) 63 (54) 0.1262b
Antiarrhythmic agent 16 (13) 6 (14) 20 (17) 0.7075b
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CLP offers a promise. The CLP score is a step in the direction of providing a more precise decision support tool 
to assist clinicians and patients in managing their CHF treatment.
Methods
Study population. This study used a sub-cohort randomly selected from the Cardiac Insufficiency Biso-
prolol Study in Elderly (CIBIS-ELD) trial, a multi-center, randomized, double-blind trial with ≥ 65-year-old 
patients being treated for CHF. The original study design and results of the CIBIS-ELD trial have been published 
 previously56,57. Briefly, patients with CHF were randomized in a 1:1 fashion to receive two different beta-block-
ers, either bisoprolol or carvedilol, and up titrated every fortnight for 12 weeks and then followed at 10 years. 
From this source cohort (n = 883), there were n = 589 with available blood samples. Patients were randomly 
selected and included in the analysis only if they passed quality  control58,59 resulting in a final set of 280 cases. 
The ethics committees of all participating centers approved the study protocol, and informed consent was signed 
by all participants prior to study participation. The ethics committees include: Germany: Ethikkommission der 
Charité on the 13th June 2007 (Amendment 5) (ref: 125/2004), Serbia: Ethics board of the University Hospital 
on the 31st March 2006 (ref: 6108/18), Slovenia: The national medical ethics committee on the 2nd July 2007 
(ref: KME 188/06/07). The investigation conformed to the principles outlined in the Declaration of  Helsinki60.
Biomarker measurements. Targeted metabolite profiling of the serum samples which passed quality 
control was performed at a specialized metabolomics lab using a commercially available kit. The kit uses a pro-
tocol based on a 1-phase extraction of the blood samples followed by gas chromatography mass spectrometry 
(GC–MS) (Agilent 6890 GC coupled to an Agilent 5973 MS-System) and liquid chromatography tandem-mass 
spectrometry (LC–MS/MS) (Agilent 1100 HPLC-System coupled to an Applied Biosystems API4000 MS/MS-
System) analysis as previously  described29. The analytical protocol was designed for routine measurement in the 
clinical practice setting; however, it is currently only available in specialized labs equipped with MS technology. 
The samples were stored at − 80 °C and transferred on dry ice prior to analysis. The three CLP metabolomic 
features and NT-proBNP measurements, were generated at baseline, only for the previously mentioned samples 
(n = 280). NT-proBNP was a measured using commercially available assays (Elecsys, Roche Diagnostics).
Calculating prognostic scores. Each prognostic score was calculated using the corresponding method 
proposed by the original authors (3–6). Only the scores which were developed in the follow-up time period, 
2006–2016, were included in the analysis due to data availability. For calculating the SHFM score, % lymphocyte 
was missing, and the median (31%) of the normal range (20–40%) was imputed for all subjects. For calculating 
Table 3.  Comparison of cohort characteristics and prognostic scores. Cohort characteristics and prognostic 
score distribution across risk clusters. The prognostic scores used for clustering were: SHFM (Seattle Heart 
Failure Model), FRS (Framingham Risk Score), and MAGGIC (Meta-analysis Global Group in Chronic 
Heart Failure), BCN Bio-HF (Barcelona Bio-Heart Failure Risk Calculator), and Cardiac Lipid Panel Risk 
Score (CLP). Each prognostic score was standardized to the same scale (mean = 0; SD = 1). Ward’s minimum 
variance method was used for clustering. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; TAG, triacylglycerol 18:1/18:0/18:0; COPD, chronic obstructive pulmonary disease; E/A, ratio of 
the early (E) to late (A) ventricular filling velocities; E/e’, ratio between early mitral inflow velocity and mitral 
annular early diastolic velocity; LAes, left atrial end systole; LDL, low-density lipoprotein; NYHA, New York 
Heart Association; HDL, high-density lipoprotein; LVDed, left ventricular diameter end diastole; LVDes, left 
ventricular diameter end systole; LVVed, left ventricular volume end diastole; LVEF, left ventricular ejection 
fraction; LVVes, left ventricular volume end systole; mg/kg, milligrams per kilograms; NTpro-BNP, N-terminal 
pro–B-type natriuretic; PC, phosphatidylcholine; SM, sphingomyelin. a Wilcoxon rank sum test, bPearson’s 
chi-square test, cMantel-Haenszel chi-square. *Imputed using the median, 31%, of the normal range 20–40%. 
† Median (Interquartile Range).
Characteristic
Cluster 1 Cluster 2 Cluster 3
p value
Low risk Moderate risk High risk
n = 119 n = 44 n = 117
Prognostic scores
SHFM, Mean (SD) 1.1 ± 0.54 0.9 ± 0.6 1.32 ± 0.5  < .0001a
FRS, Mean (SD) 20.1 ± 4.1 20.6 ± 4.5 20.1 ± 4.0 0.6033a
MAGGIC, Mean (SD) 22.1 ± 5.0 21.4 ± 3.8 22.7 ± 5.0 0.2092a
BCN Bio-HF, Mean (SD) 0.83 ± 0.17 0.34 ± 0.13 0.76 ± 0.2  < .0001a
CLP, n (%)  < .0001b
0 6 (6) 1 (3) 0 (0)
1 83 (85) 24 (75) 4 (4)
2 4 (4) 3 (9) 13 (12)
3 5 (5) 4 (13) 77 (68)
4 0 (0) 0 (0) 19 (17)
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the BCN Bio-HF score, the model with clinical variables plus NT-proBNP was used since ST-2 and hs-cTnT were 
not available. The CLP risk score was calculated as the count of biomarkers above the Youden index cut-off61. 
The Youden’s index calculates each biomarker’s optimal cut-off from the Cox regression. There were 4 cut-off 
values, since four biomarkers are included in the score: three from the CLP and NT-proBNP. Based on the cut-
off, a value of 1 or 0 was assigned if the biomarker value was above/below the cut-off value, or in the direction of 
greater risk, then all 4 values were summed to generate the final score for each subject. The score ranged from 0 
to 4, higher scores indicating higher risk. The primary outcome, cardiovascular death, was defined as death by 
myocardial infarction, non-responding arrhythmia, asystole, chronic pump failure, or other cardiac cause and 
verified by a blinded committee of cardiologists.
Statistical analysis. Power and sample Size. The sample size was adjusted for an anticipated event rate of 
0.34. A Cox regression of the log hazard ratio on a covariate with a standard deviation of 1.5 based on a sample 
of 257 observations achieves 80% power at a 0.050 significance level to detect a regression coefficient equal to 0.2. 
Adjusting for an anticipated loss to follow up rate of 10%, the final sample size would be 283.
Discrimination analysis and calibration. Categorical variables were expressed as number (%) and continuous 
variables were expressed as mean (SD). The primary outcome was 10-year cardiovascular death, and the second-
ary outcome was 3 year all-cause death, since all scores except for FRS were developed for this outcome. Cox 
Regression was performed on each of the prognostic scores, and hazard ratios and 95% confidence intervals were 
calculated to assess their relationship with the outcome.
For the survival models, integrated area under the receiver operator curves (IAUC) and Harrell’s c  statistic62 
were calculated to assess the discrimination of each score in predicting the outcome. Hypothesis testing of the 
change in discrimination was performed by calculating the differences in concordance  statistics63. The IAUC 
curves are computed as a weighted average of the AUC values at all the event times, with the weights as the 
jumps of the Kaplan–Meier estimate of the survivor function. Calibration (i.e., the agreement between observed 
outcomes and predictions) of all models was assessed graphically, with calibration plots.
Competing event and cause-specific analysis was performed for all models with non-cardiovascular mortality 
as the competing event. The cumulative incidence function (CIF) was calculated for the CLP which was stratified 
by low (CLP score 0–1), moderate (CLP score 2), and high (CLP score 3–4) to assess CIF. The discrimination 
analysis and competing event and cause-specific analysis were performed using SAS software version 9.4 of the 
SAS System for Windows (SAS Institute, Inc., Cary, North Carolina)64. Calibration was analyzed using Stata 
Statistical Software version  1665.
Cluster analysis. Hierarchical cluster analysis was performed using Ward’s minimum variance method to 
assess each prognostic score’s ability to separate cases into risk groups. The distance between two clusters is the 
ANOVA sum of squares between the clusters summed over all variables. Only the 5 risk scores used as the input 
variables for the cluster analysis to examine how well they classified patients into a low, moderate, and high-risk 
of cardiovascular mortality. Data was standardized (mean of 0 and SD of 1), to perform clustering. The clinical 
characteristics and scores were compared across risk clusters. Comparisons among continuous variables were 
performed using Wilcoxon rank sum test; and Pearson’s chi-square test (or Fisher’s exact test) or Mantel–Haen-
szel Chi-square test for categorical and ordinal data, respectively. Kaplan–Meier curves were used to compare the 
survival distribution across risk clusters. Survival time was calculated from baseline until cardiovascular death 
or censoring at 10 year follow up. Cluster analysis was performed using JMP pro software version  1466. Kaplan–
Meier curves were generated using SAS software version 9.4 of the SAS System for Windows (SAS Institute, Inc., 
Cary, North Carolina)64.
Correlation analysis. To investigate potential relationships between the CLP biomarker values and common 
clinical parameters, Pearson’s correlation coefficients were calculated, significant at the 0.01 level (2-tailed). Cor-
relation analysis was performed using R software version 3.6.167.
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